|View printer-friendly version|
|Quidel to Present at Pacific Growth Equities Life Sciences Growth Conference on June 7|
Quidel Corporation (NASDAQ:QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced that it will present at the Pacific Growth Equities 2005 Life Sciences Growth Conference to be held June 6-8, 2005 at the Inter-Continental Mark Hopkins Hotel in San Francisco.
Caren L. Mason, Quidel's President and Chief Executive Officer, is scheduled to speak on Tuesday, June 7, 2005 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) and will discuss the Company's strategic initiatives, business developments and market opportunities. Management also will be hosting an investor dinner on Tuesday evening. Interested institutional investors should contact Lippert/Heilshorn & Associates for further information.
Investors may access a live audio Internet webcast and slide presentation via the Investor Information section of the Company's Web site at www.quidel.com. A replay of the presentation and Q&A will be available for 30 days at the above Web address.
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), the portfolio currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential point-of-care applications in the future. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com.
SOURCE: Quidel Corporation